This study further confirmed the effect of PPAR α/δ dual agonist in NASH, and also provided clues for further elucidating the mechanism of PPAR α/δ agonists in the treatment of NASH. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.